On this page
Ciclopirox Olamine
Overview
Active ingredients
Source: NDC DirectoryForms, strengths and routes
Source: NDC DirectoryPharmacologic classes are listed in the class section below.
Pharmacologic class
Source: NDC Directory| Class | Type | Browse |
|---|---|---|
| Decreased DNA Replication [PE] | PE | 5 members — no class page |
| Decreased Protein Synthesis [PE] | PE | 7 members — no class page |
| Decreased RNA Replication [PE] | PE | 5 members — no class page |
| Protein Synthesis Inhibitors [MoA] | MoA | 7 members — no class page |
Regulatory status
Source: Drugs@FDANDC Directory| Product | Trade name | Form | Strength | Ingredient | Status | TE | Flags |
|---|---|---|---|---|---|---|---|
| 077676-001 | CICLOPIROX | SUSPENSION | CICLOPIROX | Prescription | AB |
Therapeutic equivalence
Source: Orange BookWhat this rating means: Therapeutically equivalent — bioequivalence demonstrated by in vivo or in vitro testing
Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.
Approval history
Source: Drugs@FDA| Type | No. | Action | Status | Date | Review |
|---|---|---|---|---|---|
| Supplement | 12 | Labeling | Approved | April 10, 2025 | Standard |
| Original application | 1 | Approved | December 15, 2006 | — |
Prescribing information
Source: openFDA Drug LabelingReproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20260416). This is the manufacturer's labelling text, not a summary and not advice.
Indications and Usage
openFDA Drug LabelingINDICATIONS AND USAGE Ciclopirox Olamine Topical Suspension USP, 0.77% (w/w) (Lotion) is indicated for the topical treatment of the following dermal infections: tinea pedis, tinea cruris and tinea corporis due to Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophyton floccosum, and Microsporum canis; cutaneous candidiasis (moniliasis) due to Candida albicans; and tinea (pityriasis) versicolor due to Malassezia furfur .
Dosage and Administration
openFDA Drug LabelingDOSAGE AND ADMINISTRATION Gently massage Ciclopirox Olamine Topical Suspension USP, 0.77% (w/w) (Lotion) into the affected and surrounding skin areas twice daily, in the morning and evening. Clinical improvement with relief of pruritus and other symptoms usually occurs within the first week of treatment. If a patient shows no clinical improvement after four weeks of treatment with Ciclopirox Olamine Topical Suspension USP, 0.77% (w/w) (Lotion) the diagnosis should be redetermined. Patients with tinea versicolor usually exhibit clinical and mycological clearing after two weeks of treatment.
Contraindications
openFDA Drug LabelingCONTRAINDICATIONS Ciclopirox Olamine Topical Suspension USP, 0.77% (w/w) (Lotion) is contraindicated in individuals who have shown hypersensitivity to any of its components.
Warnings
openFDA Drug LabelingWARNINGS General - Ciclopirox Olamine Topical Suspension USP, 0.77% (w/w) (Lotion) is not for ophthalmic use. Keep out of reach of children.
Adverse Reactions
openFDA Drug LabelingADVERSE REACTIONS In the controlled clinical trial with 89 patients using ciclopirox olamine topical suspension and 89 patients using the vehicle, the incidence of adverse reactions was low. Those considered possibly related to treatment or occurring in more than one patient were pruritus, which occurred in two patients using ciclopirox olamine topical suspension and one patient using the suspension vehicle, and burning, which occurred in one patient using ciclopirox olamine topical suspension. To report SUSPECTED ADVERSE REACTIONS, contact Padagis ® at 1-866-634-9120 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Description
openFDA Drug LabelingDESCRIPTION Ciclopirox Olamine Topical Suspension USP, 0.77% (w/w) (Lotion) is for topical use. Each gram of Ciclopirox Olamine Topical Suspension USP, 0.77% (w/w) (Lotion) contains 7.70 mg of ciclopirox (as ciclopirox olamine) in a water miscible suspension base consisting of benzyl alcohol (1% as a preservative), cetyl alcohol, lactic acid, light mineral oil, myristyl alcohol, octyldodecanol, polysorbate 60, purified water, sorbitan monostearate, and stearyl alcohol. Ciclopirox Olamine Topical Suspension USP, 0.77% (w/w) (Lotion) contains a synthetic, broad-spectrum, antifungal agent ciclopirox (as ciclopirox olamine). The chemical name is 6-cyclohexyl-1-hydroxy-4-methyl-2(1 H )-pyridone, 2-aminoethanol salt. The CAS Registry Number is 41621-49-2. Ciclopirox Olamine Topical Suspension USP, 0.77% (w/w) (Lotion) has a pH of 7. The chemical structure is:
How Supplied / Storage and Handling
openFDA Drug LabelingHOW SUPPLIED Ciclopirox Olamine Topical Suspension USP, 0.77% (w/w) (Lotion) is available as follow: NDC: 72162-1406-3: 30 mL in a BOTTLE NDC: 72162-1406-6: 60 mL in a BOTTLE Bottle space provided to allow for vigorous shaking before each use. Repackaged/Relabeled by: Bryant Ranch Prepack, Inc. Burbank, CA 91504
Adverse event reports
Source: openFDA FAERSAttributed to this product's most-reported active ingredient: CICLOPIROX OLAMINE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.
Packaging and NDCs
Source: NDC Directory| Package NDC | Product NDC | Labeler | Description | Marketing start |
|---|---|---|---|---|
| 63629-2522-1 | 63629-2522 | Bryant Ranch Prepack | 1 BOTTLE in 1 CARTON (63629-2522-1) / 30 mL in 1 BOTTLE | December 29, 2006 |
| 63629-8627-1 | 63629-8627 | Bryant Ranch Prepack | 1 BOTTLE in 1 CARTON (63629-8627-1) / 60 mL in 1 BOTTLE | December 29, 2006 |
| 71335-2717-1 | 71335-2717 | Bryant Ranch Prepack | 1 BOTTLE in 1 CARTON (71335-2717-1) / 60 mL in 1 BOTTLE | July 28, 2025 |
| 71335-2915-1 | 71335-2915 | Bryant Ranch Prepack | 1 BOTTLE in 1 CARTON (71335-2915-1) / 30 mL in 1 BOTTLE | October 24, 2025 |
| 72162-1406-3 | 72162-1406 | Bryant Ranch Prepack | 1 BOTTLE in 1 CARTON (72162-1406-3) / 30 mL in 1 BOTTLE | October 2, 2023 |
| 72162-1406-6 | 72162-1406 | Bryant Ranch Prepack | 1 BOTTLE in 1 CARTON (72162-1406-6) / 60 mL in 1 BOTTLE | October 2, 2023 |
| 45802-400-46 | 45802-400 | Padagis Israel Pharmaceuticals Ltd | 1 BOTTLE in 1 CARTON (45802-400-46) / 60 mL in 1 BOTTLE | December 29, 2006 |
| 45802-400-49 | 45802-400 | Padagis Israel Pharmaceuticals Ltd | 1 BOTTLE in 1 CARTON (45802-400-49) / 30 mL in 1 BOTTLE | December 29, 2006 |
| 63629-2522 | 63629-2522 | Bryant Ranch Prepack | — | December 29, 2006 |
| 63629-8627 | 63629-8627 | Bryant Ranch Prepack | — | December 29, 2006 |
| 71335-2717 | 71335-2717 | Bryant Ranch Prepack | — | December 29, 2006 |
| 71335-2915 | 71335-2915 | Bryant Ranch Prepack | — | December 29, 2006 |
| 72162-1406 | 72162-1406 | Bryant Ranch Prepack | — | December 29, 2006 |
| 45802-400 | 45802-400 | Padagis Israel Pharmaceuticals Ltd | — | December 29, 2006 |
Sources for this page
| Dataset | Agency | Used for |
|---|---|---|
| NDC Directory | FDA | Identity, ingredients, strengths, forms, routes, labelers, packages |
| Drugs@FDA | FDA | Application, sponsor, submissions, review documents, marketing status |
| Orange Book | FDA | Therapeutic equivalence codes, reference drug flags, patents, exclusivity |
| Drug Labeling | FDA / NLM | Prescribing information reproduced above |
| FAERS | FDA | Adverse event report counts |
Generated September 25, 2026 · 12 sections on this page.